Cyclo-Proginova® (Cyclo-Proginova®)

In the presence of several risk factors for the development of thrombosis or a high degree of severity of one of the risk factors, CyclO-Proginova is contraindicated for use (due to an increase in the likelihood of thrombosis).

Medical examinations

Before the use of the drug, and then at certain intervals during treatment (at least 1 time in 6 months) should be spend gynecological and general medical examinations, including examination of the mammary glands, measurement of blood pressure and other necessary studies.

Medical examination (including periodic determination of prolactin concentration) is necessary if the patient has an anterior pituitary adenoma.

If hormone replacement therapy is performed with one of the diseases or conditions listed below, you may need to have careful medical supervision. Therefore, if you have one of these conditions, tell your doctor before you start taking CyclO-Proginov.

-fibromyoma of the uterus;

-endometriosis at present or in the past;

- liver or gallbladder disease.After the transferred hepatitis, the administration of the drug is possible not earlier than in 6 months (before the normalization of the liver function);

-hickness in previous pregnancy or previous reception of sex hormones;

-diabetes;

- arterial hypertension (high blood pressure);

-chloasis (areas of discolored skin) now or in the past. If they are available, avoid prolonged exposure to the sun or ultraviolet radiation;

-epilepsy;

-proven diseases of mammary glands (mastopathy);

-bronchial asthma;

-migraine;

-porphyria;

-osclerosis;

- Systemic lupus erythematosus;

-chorea;

-increased risk of vein thrombosis. The risk rises with age. It can also increase in the case of past thrombosis in you or your relatives, with varicose veins; excess body weight.

The risk of deep vein thrombosis is temporarily increased as a result of surgery, serious injuries or prolonged immobility. If you are using Cyclobulin Proinova, tell your doctor about any planned hospitalization or surgery (4-6 weeks).

Do not use hormone replacement therapy to prevent heart attack or stroke.

The following warnings regarding the use of HRT should be considered when using the CyclO-Proginov preparation.

HRT and tumors

-Endometrial cancer

With prolonged use of estrogens in monotherapy, the probability of cancer of the uterine mucosa (endometrial cancer) increases. If you have a uterus preserved. You will need an additional method of progestogens. The addition of gestagens reduces the risk of endometrial cancer.

Inform your attending physician if you often have cycle irregularities or breakthrough bleeding when taking Cyclo- Proginova.

- Mammary cancer

Several studies have shown that in women who have used hormone replacement therapy (HRT) for several years, breast cancer is observed somewhat more frequently than their peers who have never used HRT. Ifnschinbut discontinues HRT, this elevated indicator is reduced in such a way that, 5 years after the abolition of HRT, the likelihood of finding breast cancer in her is the same as in women who have never used HRT.If breast cancer is detected in women using HRT, the probability of spreading the tumor to other organs is less than that of women who have never used HRT. It is not known whether this difference is explained by the use of HRT. Perhaps it is caused by the fact that women who use hormone replacement drugs are more likely to be examined, and therefore the presence of breast cancer is detected at earlier stages.

The likelihood of detecting breast cancer increases with duration of treatment, but these the rates are comparable to the increased risk of breast cancer that occur with the later onset of natural menopause. Preparations for HRT, to which Cyclo-Proginova belongs, increase the mammographic density of the milkчнglands, which in some cases may have a negative effect on X-ray detection of breast cancer. Therefore, other methods should be used to detect breast cancer.

- Liver tumors

In rare cases, with the use of sex hormones, development benign, and even less often - malignant liver tumors. In separate cases such tumors led to the development of life-threatening bleeding into the abdominal cavity.

Communication with HRT is not proven. Although such cases are extremely unlikely, you should inform your doctor if you experience unusual sensations in the upper abdomen that do not go away for a short time.

The reasons for the immediate cessation of CyclO-Proginov

You should immediately stop treatment and consult a doctor if you experience any of the following conditions:

- the first occurrence of a migraine attack (characterized by a throbbing headache and nausea, which is preceded by a visual impairment);

- exacerbation of existing migraines; any unusually frequent or unusually severe headaches;

- sudden visual or hearing impairment;

- inflammation of the veins (phlebitis).

If you have a thrombosis in the presence of Cyclo-Proginov or if you suspect that this could happen, you should immediately stop taking the drug and consult a doctor. The warning signs of a possible thrombosis are:

- coughing up blood;